000 | 01997 a2200601 4500 | ||
---|---|---|---|
005 | 20250517213918.0 | ||
264 | 0 | _c20181029 | |
008 | 201810s 0 0 eng d | ||
022 | _a1473-5687 | ||
024 | 7 |
_a10.1097/MEG.0000000000001152 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aHassany, Mohamed | |
245 | 0 | 0 |
_aHepatitis C virus treatment by direct-acting antivirals in successfully treated hepatocellular carcinoma and possible mutual impact. _h[electronic resource] |
260 |
_bEuropean journal of gastroenterology & hepatology _c08 2018 |
||
300 |
_a876-881 p. _bdigital |
||
500 | _aPublication Type: Journal Article | ||
650 | 0 | 4 | _aAged |
650 | 0 | 4 |
_aAntiviral Agents _xadverse effects |
650 | 0 | 4 | _aCarbamates |
650 | 0 | 4 |
_aCarcinoma, Hepatocellular _xdiagnosis |
650 | 0 | 4 | _aDrug Therapy, Combination |
650 | 0 | 4 |
_aEgypt _xepidemiology |
650 | 0 | 4 | _aFemale |
650 | 0 | 4 |
_aHepatitis C _xdiagnosis |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 |
_aImidazoles _xtherapeutic use |
650 | 0 | 4 | _aIncidence |
650 | 0 | 4 |
_aLiver Neoplasms _xdiagnosis |
650 | 0 | 4 | _aMale |
650 | 0 | 4 | _aMiddle Aged |
650 | 0 | 4 | _aNeoplasm Recurrence, Local |
650 | 0 | 4 | _aProspective Studies |
650 | 0 | 4 | _aPyrrolidines |
650 | 0 | 4 |
_aRibavirin _xtherapeutic use |
650 | 0 | 4 | _aRisk Factors |
650 | 0 | 4 |
_aSimeprevir _xtherapeutic use |
650 | 0 | 4 |
_aSofosbuvir _xtherapeutic use |
650 | 0 | 4 | _aSustained Virologic Response |
650 | 0 | 4 | _aTime Factors |
650 | 0 | 4 | _aTreatment Outcome |
650 | 0 | 4 |
_aValine _xanalogs & derivatives |
700 | 1 | _aElsharkawy, Aisha | |
700 | 1 | _aMaged, Amr | |
700 | 1 | _aMehrez, Mai | |
700 | 1 | _aAsem, Noha | |
700 | 1 | _aGomaa, Ahmed | |
700 | 1 | _aMostafa, Zeinab | |
700 | 1 | _aAbbas, Bahaa | |
700 | 1 | _aSoliman, Mohamad | |
700 | 1 | _aEsmat, Gamal | |
773 | 0 |
_tEuropean journal of gastroenterology & hepatology _gvol. 30 _gno. 8 _gp. 876-881 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1097/MEG.0000000000001152 _zAvailable from publisher's website |
999 |
_c28358010 _d28358010 |